WASHINGTON — President Trump’s forthcoming proposal to lower the cost of expensive physician-administered drugs will hit three drug companies — Amgen, Genentech, and Regeneron — harder than anyone else.

Trump is expected to roll out a pilot program Thursday that would tie reimbursement for certain expensive drugs to the prices paid in other similar countries, POLITICO reports. And the Department of Health and Human Services is already out with a report that names the specific drug companies that charge more for their medicines in the U.S. than in other countries.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Populism in drug pricing is great as a ploy to keep power, because people depend on the drugs we have already developed. But, if you don’t want Jim Cancer to run free, then make sure to keep the bounty high. That’s the only way we will be sure to get the best and brightest to burn the midnight oil to figure out the answers, and to get Daddy Warbucks to fork over a king’s ransom to finance research with way less than a heads-or-tails chance of success to find the holy grail for something you may one day be diagnosed with.
    Populism is the cancer. It destroys everything over a long enough time horizon. It really is that simple.

  • The majority of Americans want Medicare for All, which will be the only way to bring down these drug prices. Unfortunately we have already seen what Industry Insiders have done to drug prices. This is merely another stunt, meant to deceive the public.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy